Renaissance Technologies's IONS Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 223,607 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $17.69 M, representing 0.03% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 38 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2019, adding 1.76 M shares. Largest reduction occurred in Q4 2020, reducing 721,819 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -263,107 | Reduce 54.06% | 223,607 | $79.11 |
| Q3 2025 | +216,000 | Add 79.79% | 486,714 | $65.42 |
| Q2 2025 | +117,200 | Add 76.34% | 270,714 | $39.51 |
| Q1 2025 | -52,000 | Reduce 25.30% | 153,514 | $30.17 |
| Q4 2024 | +15,000 | Add 7.87% | 205,514 | $34.96 |
| Q3 2024 | -59,000 | Reduce 23.65% | 190,514 | $40.06 |
| Q2 2024 | +69,800 | Add 38.84% | 249,514 | $47.66 |
| Q1 2024 | +67,300 | Add 59.87% | 179,714 | $43.35 |
| Q4 2023 | -157,386 | Reduce 58.33% | 112,414 | $50.59 |
| Q3 2023 | -100,700 | Reduce 27.18% | 269,800 | $45.36 |
| Q2 2023 | -265,814 | Reduce 41.77% | 370,500 | $0.04 |
| Q1 2023 | -542,500 | Reduce 46.02% | 636,314 | $0.04 |
| Q4 2022 | +311,100 | Add 35.85% | 1.18 M | $0.04 |
| Q3 2022 | +252,900 | Add 41.13% | 867,714 | $44.23 |
| Q2 2022 | +479,900 | Add 355.71% | 614,814 | $37.02 |
| Q1 2022 | -95,900 | Reduce 41.55% | 134,914 | $37.04 |
| Q4 2021 | +133,100 | Add 136.21% | 230,814 | $30.43 |
| Q3 2021 | -678,700 | Reduce 87.41% | 97,714 | $33.54 |
| Q2 2021 | +189,000 | Add 32.17% | 776,414 | $39.89 |
| Q1 2021 | -157,934 | Reduce 21.19% | 587,414 | $44.96 |
| Q4 2020 | -721,819 | Reduce 49.20% | 745,348 | $56.54 |
| Q3 2020 | -285,700 | Reduce 16.30% | 1.47 M | $47.45 |
| Q2 2020 | +64,456 | Add 3.82% | 1.75 M | $58.96 |
| Q1 2020 | -350,300 | Reduce 17.18% | 1.69 M | $47.28 |
| Q4 2019 | +225,700 | Add 12.45% | 2.04 M | $60.41 |
| Q3 2019 | +57,700 | Add 3.29% | 1.81 M | $59.91 |
| Q2 2019 | +1.76 M | New Buy | 1.76 M | $64.27 |
| Q3 2018 | -109,914 | Sold Out | 0 | $0.00 |
| Q2 2018 | -117,800 | Reduce 51.73% | 109,914 | $41.67 |
| Q1 2018 | +227,714 | New Buy | 227,714 | $44.08 |
| Q3 2017 | -82,414 | Sold Out | 0 | $0.00 |
| Q2 2017 | -230,800 | Reduce 73.69% | 82,414 | $50.87 |
| Q1 2017 | -136,300 | Reduce 30.32% | 313,214 | $40.20 |
| Q4 2016 | +174,700 | Add 63.57% | 449,514 | $47.83 |
| Q3 2016 | +91,714 | Add 50.09% | 274,814 | $36.64 |
| Q2 2016 | +123,700 | Add 208.25% | 183,100 | $23.29 |
| Q1 2016 | -75,914 | Reduce 56.10% | 59,400 | $40.51 |
| Q4 2015 | +135,314 | New Buy | 135,314 | $61.93 |
Renaissance Technologies's Ionis Pharmaceuticals Investment FAQs
Renaissance Technologies first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2015, acquiring 135,314 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Ionis Pharmaceuticals, Inc. (IONS) for 38 quarters since Q4 2015.
Renaissance Technologies's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q2 2019, adding 1,755,311 shares worth $112.81 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 223,607 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $17.69 M.
As of the Q4 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.03% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 2,038,711 shares, as reported at the end of Q4 2019.